Herpetiform pemphigus

Herpetiform pemphigus is a rare variant of pemphigus, a group of autoimmune blistering diseases that affect the skin. It is classified under ICD-10 as L10.8 (other pemphigus). This condition is characterized by the formation of clusters of small, itchy vesicles and blisters on the skin that resemble the lesions seen in dermatitis herpetiformis, hence the name 'herpetiform.' Unlike classic pemphigus vulgaris or pemphigus foliaceus, the blisters in herpetiform pemphigus tend to be arranged in an annular or grouped (herpetiform) pattern. Patients typically experience significant pruritus (itching), which is unusual for most forms of pemphigus. The condition primarily affects the skin, with lesions commonly appearing on the trunk, proximal extremities, and sometimes the face. Mucosal involvement is generally less common than in classic pemphigus vulgaris. Histologically, herpetiform pemphigus may show eosinophilic spongiosis or mild acantholysis in the early stages, which can make initial diagnosis challenging. Immunologically, patients demonstrate intercellular IgG deposits in the epidermis on direct immunofluorescence, similar to other forms of pemphigus. Circulating autoantibodies against desmoglein 1 and/or desmoglein 3 (desmosomal adhesion proteins) may be detected. Some cases have been associated with antibodies against desmocollin. Treatment follows the general approach used for pemphigus and typically involves systemic corticosteroids as first-line therapy. Steroid-sparing immunosuppressive agents such as azathioprine, mycophenolate mofetil, or dapsone may be used as adjunctive therapy. Dapsone has been reported to be particularly effective in some cases of herpetiform pemphigus. The prognosis is generally considered more favorable than classic pemphigus vulgaris, though the disease may follow a relapsing course. Close monitoring and long-term follow-up by a dermatologist experienced in autoimmune blistering diseases is recommended.

Common questions about Herpetiform pemphigus